Manuel Barreiro-de Acosta Selected Research

Infliximab (Remicade)

1/2024	Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
7/2022	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
3/2021	Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn's disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain.
1/2020	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease.
1/2019	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.
2/2016	Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
10/2015	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
1/2015	Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.
10/2012	Effectiveness of infliximab after adalimumab failure in Crohn's disease.
7/2012	Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuel Barreiro-de Acosta Research Topics

Disease

38	Crohn Disease (Crohn's Disease) 01/2024 - 01/2007
30	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2024 - 09/2011
28	Ulcerative Colitis 01/2024 - 08/2009
6	Pouchitis 01/2024 - 07/2012
5	Necrosis 01/2021 - 01/2015
3	COVID-19 11/2023 - 01/2022
3	Fistula 01/2023 - 01/2015
3	Latent Tuberculosis 01/2021 - 07/2017
3	Colitis 01/2019 - 07/2010
2	Infections 11/2023 - 11/2020
2	Inflammation (Inflammations) 01/2023 - 01/2021
1	Intestinal Failure 06/2023
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2023
1	Pulmonary Embolism 01/2023
1	Thrombosis (Thrombus) 01/2023
1	Pathologic Constriction (Stenosis) 01/2023
1	Stillbirth 09/2022
1	Spontaneous Abortion (Miscarriage) 09/2022
1	Pain (Aches) 01/2022
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Tuberculosis (Tuberculoses) 01/2021
1	Psoriatic Arthritis 01/2021
1	Hepatitis B 11/2020
1	Skin Diseases (Skin Disease) 01/2020
1	Myocardial Infarction 01/2020
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2020
1	Disease Progression 10/2018
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 03/2018
1	Colorectal Neoplasms (Colorectal Cancer) 03/2016
1	Iron Deficiencies 10/2013
1	Anemia 10/2013
1	Microscopic Colitis 04/2013
1	Drug-Related Side Effects and Adverse Reactions 09/2011

Drug/Important Bio-Agent (IBA)

13	Infliximab (Remicade)FDA Link 01/2024 - 08/2009
11	Adalimumab (Humira)FDA Link 01/2023 - 08/2009
9	Ustekinumab (CNTO 1275)FDA Link 07/2023 - 01/2020
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 03/2013
6	SteroidsIBA 01/2023 - 01/2007
5	vedolizumabIBA 07/2023 - 12/2019
5	Biomarkers (Surrogate Marker)IBA 03/2022 - 01/2015
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 12/2009
4	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2019 - 01/2016
3	Immunosuppressive Agents (Immunosuppressants)IBA 11/2023 - 07/2017
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2020
3	2-mercaptopurineIBA 03/2016 - 04/2013
2	COVID-19 VaccinesIBA 11/2023 - 12/2022
2	Immunologic Factors (Immunomodulators)IBA 01/2023 - 01/2021
2	tofacitinibIBA 01/2023 - 01/2021
2	Biosimilar PharmaceuticalsIBA 01/2023 - 03/2021
2	Tuberculin (PPD)IBA 11/2018 - 07/2017
2	Ferritins (Ferritin)IBA 03/2018 - 10/2013
2	Beclomethasone (Beclometasone)FDA Link 04/2013 - 12/2010
1	Trace Elements (Biometals)IBA 01/2024
1	Heavy MetalsIBA 01/2024
1	teduglutideIBA 06/2023
1	VaccinesIBA 12/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	RadonIBA 01/2022
1	Tumor Necrosis FactorsIBA 06/2021
1	HomoserineIBA 01/2021
1	Methionine (L-Methionine)FDA Link 01/2021
1	Proline (L-Proline)FDA Link 01/2021
1	CreatinineIBA 01/2021
1	CreatineIBA 01/2021
1	Essential Amino AcidsIBA 01/2021
1	Tryptophan (L-Tryptophan)FDA Link 01/2021
1	Immunomodulating AgentsIBA 01/2021
1	FendrixIBA 11/2020
1	Engerix-BIBA 11/2020
1	AntibodiesIBA 12/2019
1	IntegrinsIBA 12/2019
1	Monoclonal AntibodiesIBA 12/2019
1	AcidsIBA 10/2018
1	Hemoglobins (Hemoglobin)IBA 03/2018
1	golimumab FDA Link 01/2017
1	P-2 (P 2)IBA 04/2015
1	Transferrin (beta 2 Transferrin)IBA 10/2013
1	Budesonide (Pulmicort)FDA LinkGeneric 04/2013
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 12/2011
1	Methotrexate (Mexate)FDA LinkGeneric 10/2011
1	EnzymesIBA 09/2011
1	Azathioprine (Imuran)FDA LinkGeneric 09/2011

Therapy/Procedure

34	Therapeutics 01/2024 - 12/2009
4	Blood Component Removal (Apheresis) 01/2024 - 08/2018
4	Biological Therapy 01/2023 - 08/2009
4	Restorative Proctocolectomy 01/2023 - 11/2019
2	Complementary Therapies (Alternative Medicine) 01/2019 - 11/2012
1	Total Parenteral Nutrition 06/2023
1	Operative Surgical Procedures 01/2023
1	Colonic Pouches (S Pouch) 01/2023
1	Cesarean Section (Caesarean Section) 09/2022
1	Bathroom Equipment 01/2022
1	Precision Medicine 12/2021
1	Chemoprevention 01/2021
1	Drug Therapy (Chemotherapy) 04/2013